Is Hand Arthritis Embolization Covered by Insurance?

Quick Answer

No insurer policy we found names embolization for hand or finger arthritis. Payer documents that address joint embolization cover the knee and classify it as investigational or not medically necessary, so expect your plan to review hand embolization as investigational. The office verifies your benefits before treatment.

Insurance questions about hand and finger embolization are hard to answer with a simple yes or no, because the procedure is new enough that insurers have not written rules for it. This page explains what the published payer documents do say, why the hand is missing from them, what "off-label" means here, and what to ask your own plan. It does not quote prices, and it does not say what any plan will decide for you.

The short answer

As of October 2026, we found no insurer medical policy that names embolization for hand or finger arthritis. The payer documents that discuss embolization for joint pain are about the knee, and they classify knee embolization as investigational, unproven or not medically necessary. Two of them also say that any embolization use they do not list is treated as not medically necessary.

Hand embolization has much less research behind it than knee embolization. You should expect a plan to review it as investigational. The only way to know how your plan will handle it is to ask, and our office verifies your benefits before treatment.

Why no policy names the hand

Hand embolization is new, and the research behind it is thin.

The published evidence is five small studies with 204 patients in total. All are uncontrolled case series, and there is no randomized trial.
It is not mentioned in the American College of Rheumatology hand osteoarthritis guidance from 2019 or 2026, or in the European EULAR 2018 recommendations.
A 2026 independent review of musculoskeletal embolization rated finger joints and the thumb base as "hypothesis-generating."
We found only one published U.S. series, with 14 patients.

Our research summary walks through each study.

What four payer documents say

We opened each of these documents on October 12, 2026. None of them mentions the hand, the fingers or the thumb.

Payer document	Dates on the document	What it says about embolization for joint pain
Aetna Clinical Policy Bulletin 0856, "Embolization: Selected Procedures"	Effective July 30, 2013; last review January 12, 2026	Lists genicular (knee) artery embolization for osteoarthritis-related knee pain among experimental, investigational or unproven procedures. No entry for the hand or any other non-knee joint.
Cigna, eviCore Peripheral Vascular Intervention Guidelines V2.0.2024	Effective January 24, 2025	Names genicular artery embolization as not medically necessary, along with "all other indications not listed in this guideline." Hand arthritis is not a listed indication.
Anthem / Elevance, Carelon guideline "Vascular Embolization and Occlusion Procedures"	Effective November 15, 2026; last review April 15, 2026	"Indications, diagnoses, or procedures not specifically addressed are considered not medically necessary." States that genicular artery embolization is not medically necessary.
UnitedHealthcare provider news notice	Posted September 1, 2026; policy effective December 1, 2026	Announces a new vascular embolization policy and prior authorization for CPT code 37242. The notice does not name knee, hand or other musculoskeletal uses.

A few cautions about this table. The Cigna document is the version we could open, and a newer one may exist. We could not find the text of the UnitedHealthcare policy itself, only the notice announcing it. The Aetna bulletin listed its next review for October 8, 2026, so its wording may change. And a national policy document is not the same thing as your individual plan's benefits.

How to read "not listed"

The Cigna and Carelon documents use a catch-all. If a use of embolization is not on their list, they treat it as not medically necessary. Cigna's guideline gives its reason: "the lack of evidence supporting the clinical benefit over other treatments." Hand arthritis is not on either list.

That is a statement about how those documents are written. It is not a prediction about your claim, and it does not describe every insurer.

Questions about your treatment options? Dr. Fox can help.

Book a Consultation

This article is part of our Embolization Guide.

What "off-label" means for this procedure

Off-label status is part of the picture. Here is what the sources say.

Nearly all published hand embolization studies used imipenem/cilastatin. It is an intravenous antibiotic, and its FDA label covers serious bacterial infections. The label says nothing about embolization or injection into an artery. Using it as a short-acting embolic is therefore off-label. A 2025 review by U.S. authors states plainly that it is not approved by the FDA for knee embolization, and a 2026 review describes it as off-label "in many settings."

Other embolic materials are in a similar position for joint pain. A 2026 expert consensus on knee embolization reported that, in the United States, the particle embolics studied for the knee had received Investigational Device Exemption or Breakthrough Device designation and "remain off-label pending regulatory approval." That statement is about the knee. Nothing comparable has been published for the hand.

Put simply, no embolic material has FDA approval or clearance specifically for hand or finger arthritis. Which material is used in the hand in U.S. practice is not documented in the published studies. The one U.S. series does not name its agent in its summary.

What to ask your plan

Call the member services number on your card and take notes, including the date and the name of the person you spoke with. Useful questions:

Do you have a medical policy on embolization for joint or musculoskeletal pain? What is its name and effective date?
Does that policy address the hand, or only the knee?
How does my plan handle procedures it classifies as investigational or not medically necessary?
Is prior authorization required, and who submits it?
If a request is denied, what is the appeal process and what records would you need?
Are the consultation and any imaging handled separately from the procedure itself?
Can you send me the answer in writing?

Ask our office which diagnosis and procedure codes would be submitted, so you and your plan are discussing the same thing.

How our office handles it

Dr. David Fox evaluates patients for hand and finger embolization at Fox Vein & Vascular in Manhattan. Before any treatment is scheduled, the office verifies your benefits with your plan. You should know where you stand before you decide.

The consultation is also where you find out whether the procedure fits you at all. Some people are better served by a splint, an injection or a hand surgery opinion. See am I a candidate and embolization vs. injections and surgery. General information about working with our office is on our insurance page.

What could change

Policies and research are both moving.

Policies. The Carelon guideline takes effect November 15, 2026, and the UnitedHealthcare policy on December 1, 2026. Aetna's bulletin was due for review in October 2026.
Research. The only registered trial specific to the hand is a 15-patient pilot in France that is still recruiting, with completion estimated for July 2028. It has no comparison group. We found no registered randomized trial for the hand.
Guidelines. The full text of the 2026 American College of Rheumatology update has not been published yet. Its summary does not mention embolization.

Until controlled trials are done, the honest expectation is that insurers will review hand embolization as investigational.

For an overview of the procedure, visit our hand arthritis embolization page. For how embolization is used in other joints, see the embolization guide.

Frequently Asked Questions

Does any insurance policy mention hand or finger embolization?

Not that we found. The Aetna, Cigna (eviCore), Carelon and UnitedHealthcare documents we opened in October 2026 do not mention the hand, fingers or thumb.

Why would an insurer call hand embolization investigational?

The published evidence is five small studies with 204 patients and no comparison groups, and the American and European hand osteoarthritis guidelines do not mention the procedure. Insurers that address knee embolization, which has more evidence, already classify it as investigational or not medically necessary.

Is the material used in hand embolization approved for this use?

No embolic material has FDA approval or clearance specifically for hand or finger arthritis. Nearly all published hand studies used imipenem/cilastatin, an antibiotic used off-label as a short-acting embolic.

Will I know my coverage before the procedure?

The office verifies your benefits with your plan before treatment is scheduled, but a benefits check is not a promise of payment. Ask your plan for its answer in writing. It also helps to call your plan yourself and ask for its answer in writing.

Keep Reading

Sources

Medically reviewed by David Fox, MD, FACS, RPVI. This article is general information, not a substitute for a medical evaluation.

Living with joint or tendon pain that hasn’t improved? Schedule a consultation with Dr. David Fox at Fox Vein & Vascular in Manhattan to find out whether embolization is right for you. Call (212) 362-3470 or request an appointment online.